Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Annabelle L. Fonseca

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4972-5139; OpenAlex author ID A5028310613. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
2
Collaborators
14
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 4 papers · 2023: 3 papers · 2024: none · 2025: 3 papers · 2026: 4 papers

Papers 15

  1. Leveraging large language models to automate scoping reviews: A case study in treatment options for pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2025.116764↗
  2. Biology vs Barriers: The Impact of Socioeconomic Disadvantage on Overall Survival in Pancreatic Cancer Despite Guideline-Concordant Treatment. Co-author DOI 10.1097/xcs.0000000000001754↗
  3. Determinants of Non-Receipt of Guideline-Concordant Treatment in Pancreatic Cancer: A Classification Tree Analysis. Last author DOI 10.1245/s10434-026-20369-x↗
  4. ASO Visual Abstract: Determinants of Non-Receipt of Guideline-Concordant Treatment in Pancreatic Cancer: A Classification Tree Analysis. Last author DOI 10.1245/s10434-026-20457-y↗
  5. Disparities in access to surgical resection in patients with pancreatic cancer - a systematic review. Last author DOI 10.1016/j.gassur.2025.102037↗
  6. Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-Analysis. Last author DOI 10.1016/j.jss.2025.04.042↗
  7. Corrigendum to 'Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-analysis' Jou… Last author DOI 10.1016/j.jss.2025.10.015↗
  8. Association between Rural Residence and Processes of Care in Pancreatic Cancer Treatment. Last author DOI 10.1007/s11605-023-05764-z↗
  9. Palliative Therapies in Metastatic Pancreatic Cancer: Does Medicaid Expansion Make a Difference? Last author DOI 10.1245/s10434-022-12563-4↗
  10. ASO Author Reflections: Disparities in Receipt of Palliative Therapies for Pancreatic Cancer: Did Medicaid Expansion Help? Last author DOI 10.1245/s10434-022-12638-2↗
  11. Fragmentation of Care in Pancreatic Cancer: Effects on Receipt of Care and Survival. Last author DOI 10.1007/s11605-022-05478-8↗
  12. Association of Medicaid Expansion with Pancreatic Cancer Treatment and Outcomes: Evidence from the National Cancer Database. Co-author DOI 10.1245/s10434-021-10709-4↗
  13. ASO Author Reflections: The Challenge of Achieving High-Quality, Equitable Care for Pancreatic Cancer: Might Medicaid Expansion Be a Piece of the Puzzle? Co-author DOI 10.1245/s10434-021-10713-8↗
  14. Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review. Co-author DOI 10.1245/s10434-021-11258-6↗
  15. Surgery for pancreatic cancer: critical radiologic findings for clinical decision making. Co-author DOI 10.1007/s00261-017-1332-z↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Martin J. Heslin · 10 shared papers, 2022–2026 · strength 2.22
  2. Manish Tripathi · 5 shared papers, 2023–2026 · strength 1.46
  3. Hamza Khan · 6 shared papers, 2022–2025 · strength 1.23
  4. Fabian Mc. Johnston · 6 shared papers, 2022–2023 · strength 1.22
  5. Chandler A. Annesi · 3 shared papers, 2025–2026 · strength 0.85
  6. Krisha Amin · 3 shared papers, 2023–2026 · strength 0.72
  7. John Bart Rose · 2 shared papers, 2025 · strength 0.54
  8. Sushanth Reddy · 2 shared papers, 2025 · strength 0.54
  9. Michelle M. Holland · 2 shared papers, 2025 · strength 0.54
  10. Vikas Dudeja · 2 shared papers, 2025 · strength 0.54
  11. Michelle M. Holland · 2 shared papers, 2025–2026 · strength 0.53
  12. Hop S. Tran Cao · 2 shared papers, 2022 · strength 0.43
  13. Jason B. Fleming · 1 shared paper, 2018 · strength 0.17
  14. Ching-Wei David Tzeng · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.